Roivant Sciences (ROIV) Gross Profit (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Gross Profit came in at $4.8 million in Q4 2025, down 77.02% YoY from $20.8 million in Q4 2024, and up 227.05% on a QoQ basis from $1.5 million in Q3 2025.
Roivant Sciences (ROIV) Gross Profit (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Gross Profit data on file, last reported at $4.8 million in Q4 2025.
- Quarterly Gross Profit fell 77.02% year-over-year to $4.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $29.0 million (down 47.3% YoY) and the FY2026 annual result came in at $7.0 million, down 75.21% from the prior year.
- Gross Profit grew to $4.8 million in Q4 2025, from $1.5 million in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $37.6 million in Q4 2021 to a low of $1.5 million in Q3 2025.
- A 5-year average of $11.5 million and a median of $7.6 million in 2021 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2021 — Gross Profit surged 1150.99% — and 2025, when it plunged 77.02%.
- Tracing ROIV's Gross Profit over 5 years: stood at $37.6 million in 2021, then slumped by 33.56% to $25.0 million in 2022, then fell by 10.66% to $22.3 million in 2023, then slipped by 6.79% to $20.8 million in 2024, then sank by 77.02% to $4.8 million in 2025.
- The last three Gross Profit figures came in at $4.8 million (Q4 2025), $1.5 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.16 Mn |
| Jun 30, 2026 | 1.16 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Dec 31, 2025 | 4.78 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 2.02 Mn |
| Jun 30, 2025 | 2.02 Mn |
| Dec 31, 2024 | 20.78 Mn |
| Dec 31, 2024 | 20.78 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | 7.78 Mn |
| Jun 30, 2024 | 7.78 Mn |
| Dec 31, 2023 | 22.29 Mn |
| Dec 31, 2023 | 22.29 Mn |
| Sep 30, 2023 | 3.43 Mn |
| Sep 30, 2023 | 3.43 Mn |
| Jun 30, 2023 | 17.41 Mn |
| Jun 30, 2023 | 17.41 Mn |